Rashtriya Newsflash

“Night Vision Disturbances Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Night Vision Disturbances Market.

The Night Vision Disturbances Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Night Vision Disturbances Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/night-vision-disturbances-pipeline-insight

Some of the key takeaways from the Night Vision Disturbances Pipeline Report:

• Companies across the globe are diligently working toward developing novel Night Vision Disturbances treatment therapies with a considerable amount of success over the years.

• Night Vision Disturbances companies working in the treatment market are Opus Genetics Inc., Viatris Inc., Nevakar Inc., Vyluma Inc., Pfizer, Allergan, AbbVie, Novartis, Bausch + Lomb, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, and others, are developing therapies for the Night Vision Disturbances treatment

• Emerging Night Vision Disturbances therapies in the different phases of clinical trials are- RYZUMVI (Phentolamine ophthalmic solution 0.75%), NVK-031, Pilocarpine, Brimonidine Tartrate, Aceclidine, Vitamin A supplementation, Gene therapy approaches (Luxturna), and others are expected to have a significant impact on the Night Vision Disturbances market in the coming years.

• In June 2025, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company advancing gene therapies for inherited retinal diseases (IRDs) and small molecule treatments for other eye disorders, announced positive topline results from LYNX-2, its pivotal Phase 3 trial. The study evaluated Phentolamine Ophthalmic Solution 0.75% for addressing significant, chronic night driving difficulties in keratorefractive patients with impaired mesopic vision.

• In February 2025, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotech company focused on developing gene therapies for inherited retinal diseases (IRDs) and other eye disorders, has announced the completion of patient enrollment in the VEGA-3 Phase 3 clinical trial of Phentolamine Ophthalmic Solution 0.75% for treating presbyopia. Additionally, the company reported that enrollment in the LYNX-2 pivotal Phase 3 trial targeting visual loss in low light conditions following keratorefractive surgery is progressing well, with enrollment expected to be completed in the first half of 2025.

• In September 2024, Johnson & Johnson, a global leader in eye care, announced the expanded U.S. launch of its latest presbyopia-correcting intraocular lens (PC-IOL), TECNIS Odyssey. This innovative IOL delivers an unparalleled continuous range of vision, allowing patients to see clearly from far to near and intermediate distances, significantly reducing the need for glasses. Built on the TECNIS platform, TECNIS Odyssey offers double the contrast in low-light conditions compared to PanOptix. Additionally, patients with TECNIS Odyssey IOL can read 14% smaller print on average than those with PanOptix IOL, and 93% reported no or mild visual disturbances such as halos, glare, or starbursts one month post-surgery.

• In January 2024, Ocuphire Pharma secured US FDA Agreement under an SPA, leading to the initiation of the LYNX-2 Phase III trial in April 2024 to evaluate Phentolamine Ophthalmic Solution for improving night vision post-refractive surgery.

Night Vision Disturbances Overview

Night vision disturbances refer to difficulty seeing clearly in low-light or dark conditions. They can affect a person’s ability to drive at night, recognize objects, or adapt quickly when moving from bright to dim environments.

Explore the latest Night Vision Disturbances pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Night Vision Disturbances Clinical Trials

Emerging Night Vision Disturbances Drugs Under Different Phases of Clinical Development Include:

• RYZUMVI (Phentolamine ophthalmic solution 0.75%): Ocuphire Pharma/ Viatris

• NVK-031: Nevakar Inc.

• Pilocarpine: Various generic manufacturers

• Brimonidine Tartrate: Allergan / AbbVie

• Aceclidine: Sun Pharmaceutical Industries Ltd. / Teva Pharmaceutical Industries Ltd.

• Luxturna (voretigene neparvovec): Novartis

• Vitamin A Supplementation: Bausch + Lomb / Various manufacturers

• Gene Therapy Approaches: Novartis, Opus Genetics

• Retinal Implants: Various research institutions

• Meclizine and related agents: Pfizer / Various manufacturers

Night Vision Disturbances Route of Administration

Night Vision Disturbances pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Night Vision Disturbances Molecule Type

Night Vision Disturbances Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Night Vision Disturbances Pipeline Therapeutics Assessment

• Night Vision Disturbances Assessment by Product Type

• Night Vision Disturbances By Stage and Product Type

• Night Vision Disturbances Assessment by Route of Administration

• Night Vision Disturbances By Stage and Route of Administration

• Night Vision Disturbances Assessment by Molecule Type

• Night Vision Disturbances by Stage and Molecule Type

DelveInsight’s Night Vision Disturbances Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Night Vision Disturbances product details are provided in the report. Download the Night Vision Disturbances pipeline report to learn more about the emerging Night Vision Disturbances therapies at:

Some of the key companies in the Night Vision Disturbances Therapeutics Market include:

Key companies developing therapies for Night Vision Disturbances are – Opus Genetics Inc., Pfizer, Vyluma Inc., Meda Pharmaceuticals, AbbVie, Novartis, Teva Pharmaceutical Industries Ltd., Bausch + Lomb, Allergan, Sun Pharmaceutical Industries Ltd., Nevakar Inc., Viatris Inc., and others.

Night Vision Disturbances Pipeline Analysis:

The Night Vision Disturbances pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Night Vision Disturbances with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Night Vision Disturbances Treatment.

• Night Vision Disturbances key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Night Vision Disturbances Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Night Vision Disturbances market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Night Vision Disturbances drugs and therapies

Night Vision Disturbances Pipeline Market Drivers

• Rising prevalence of night vision disturbances, with millions of diagnosed cases globally, increasing demand for effective therapies

• Growing aging population, leading to higher incidence of age-related vision issues such as presbyopia and retinal disorders

• Increasing cases of retinal degeneration affecting rod cells responsible for low-light vision

• Advancements in gene therapy, retinal implants, and neurostimulation technologies improving treatment outcomes

Night Vision Disturbances Pipeline Market Barriers

• High cost of advanced treatments, including gene therapies and novel ophthalmic drugs

• Limited availability of approved therapies, especially for specific causes like post-refractive surgery disturbances

• Regulatory challenges and lengthy approval processes for new ophthalmic drugs

• Reimbursement issues due to inconsistent coverage and lack of standardized treatment pathways

• Complexity of underlying causes (multifactorial etiology) making treatment development difficult

• Low diagnosis rates and underreporting of symptoms in early stages

Scope of Night Vision Disturbances Pipeline Drug Insight

• Coverage: Global

• Key Night Vision Disturbances Companies: Opus Genetics Inc., Viatris Inc., Nevakar Inc., Vyluma Inc., Pfizer, Allergan, AbbVie, Novartis, Bausch + Lomb, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, and others

• Key Night Vision Disturbances Therapies: RYZUMVI (Phentolamine ophthalmic solution 0.75%), NVK-031, Pilocarpine, Brimonidine Tartrate, Aceclidine, Vitamin A supplementation, Gene therapy approaches (Luxturna), and others

• Night Vision Disturbances Therapeutic Assessment: Night Vision Disturbances current marketed and Night Vision Disturbances emerging therapies

• Night Vision Disturbances Market Dynamics: Night Vision Disturbances market drivers and Night Vision Disturbances market barriers

Request for Sample PDF Report for Night Vision Disturbances Pipeline Assessment and clinical trials

Table of Contents

1. Night Vision Disturbances Report Introduction

2. Night Vision Disturbances Executive Summary

3. Night Vision Disturbances Overview

4. Night Vision Disturbances- Analytical Perspective In-depth Commercial Assessment

5. Night Vision Disturbances Pipeline Therapeutics

6. Night Vision Disturbances Late Stage Products (Phase II/III)

7. Night Vision Disturbances Mid Stage Products (Phase II)

8. Night Vision Disturbances Early Stage Products (Phase I)

9. Night Vision Disturbances Preclinical Stage Products

10. Night Vision Disturbances Therapeutics Assessment

11. Night Vision Disturbances Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Night Vision Disturbances Key Companies

14. Night Vision Disturbances Key Products

15. Night Vision Disturbances Unmet Needs

16 . Night Vision Disturbances Market Drivers and Barriers

17. Night Vision Disturbances Future Perspectives and Conclusion

18. Night Vision Disturbances Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/